News for Healthier Living

Improving Treatment for an Autoimmune Bleeding Condition

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

December 9, 2025


December 12 2025

December 11 2025

December 10 2025

December 9 2025

December 8 2025

December 7 2025

December 6 2025

December 5 2025

December 4 2025

December 3 2025

December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025